Forge Biologics

At the forefront of genetic medicine, Forge Biologics is revolutionizing the landscape of gene therapy through its advanced development and manufacturing capabilities. Operating as a key member of Ajinomoto Bio-Pharma Services, the company serves as a vital engine for innovation, dedicated to making life-altering gene therapies accessible to patients worldwide. Through groundbreaking technology and a patient-first philosophy, Forge Biologics partners with the brightest minds in the field—including scientists, physicians, and biotech companies—to navigate the complex journey from initial concept to clinical reality. The company's core mission is to accelerate the development of transformative treatments for rare and devastating genetic diseases, offering hope where there was none before. This is achieved through a unique, hybrid model that combines contract development and manufacturing (CDMO) services with its own clinical-stage therapeutics pipeline.

The heart of Forge's operation is 'the Hearth,' a state-of-the-art, 200,000-square-foot cGMP facility in Columbus, Ohio, which stands as a testament to their commitment to excellence. This facility is custom-designed for AAV (adeno-associated virus) vector manufacturing, featuring 20 cGMP suites and a bioreactor capacity of 20,000L. Innovation is further embedded in their proprietary FUEL™ manufacturing platform, which incorporates novel technologies like Ignition Cells™ and pEMBR™ 2.0 Ad Helper to create a more efficient, scalable, and potentially safer foundation for AAV production. By providing end-to-end, scalable services—from process and analytical development to final fill and integrated regulatory support—Forge Biologics is not just a service provider but a dedicated partner, forging new pathways to bring groundbreaking genetic medicines from the lab bench to the patient's bedside with unprecedented speed and precision.